The success of biosimilars will depend on a range of factors, including local policies on interchangeability, harmonization of naming conventions, reimbursement decisions, and physician adoption. Real-world evidence will help support data generated by clinical trials and fill the evidence gap for doctors, patients, and payers.

Authors: Jaclyn Bosco, PhD, MPH and Nancy Dreyer, PhD, MPH